
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
With recent FDA Guidance on Clinical Trials COVID-19 suggesting, “If planned on-site monitoring visits are no longer possible, sponsors should consider optimizing the use of central and remote monitoring programs to maintain oversight of clinical sites," Risk-Based Quality Management (RBQM) solutions provider Cyntegrity is offering its special






